SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA) Files An 8-K Entry into a Material Definitive Agreement

SIGA TECHNOLOGIES, INC. (OTCMKTS:SIGA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

On August 10, 2018, SIGA Technologies, Inc., a Delaware corporation (the “Company”), entered into an Addendum (the “Hruby Addendum”) to its Second Amended and Restated Employment Agreement with its Vice President and Chief Scientific Officer, Dr. Dennis E. Hruby (the “Existing Hruby Agreement”). A copy of the Existing Hruby Agreement was filed with the Securities and Exchange Commission as an exhibit to the Company’s Current Report on Form 8-K dated April 14, 2016. The Hruby Addendum supplements the Existing Hruby Agreement by providing for two potential cash milestone bonuses of $200,000 each to Dr. Hruby, the first of which will be earnedon December 31, 2019 providedDr. Hrubyis still employed by the Company and performing the functions of Chief Scientific Officer of the Company substantially in accordance with his current job responsibilities, and the second of which will be earned on December31, 2020 provided Dr. Hrubyis so employed and performing in accordance with current job responsibilities. The Hruby Addendum does not otherwise modify the Existing Hruby Agreement.

The foregoing description is qualified in its entirety by reference to the Hruby Addendum, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The disclosure contained in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 5.02.

Item 9.01. Financial Statements and Exhibits

(d) The following exhibits are included in this report:




Addendum, dated August 10, 2018 to Seconded Amended and Restated Employment Agreement, dated April 12, 2016, between SIGA Technologies, Inc. and Dennis E. Hruby.

EX-10.1 2 ex10_1.htm EXHIBIT 10.1 Exhibit 10.1   August 10,…
To view the full exhibit click here


SIGA Technologies, Inc. (SIGA) is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses. Tecovirimat is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). Tecovirimat is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. Tecovirimat has Orphan Drug designation for both the treatment and prevention of smallpox, and the treatment of orthopoxvirus infections (vaccinia, variola, monkeypox and cowpox). The Company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture Tecovirimat. The Company also has a lead pre-clinical drug candidate with activity against approximately four serotypes of the dengue virus.

An ad to help with our costs